VA
EWTX icon

VR Adviser’s Edgewise Therapeutics EWTX Stock Holding History

VR Adviser’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000,000
Closed -$26.7M – 41
2024
Q3 		$26.7M Sell
1,000,000
-818,182
-45% -$16.3M 1.4% 21
2024
Q2 		$32.7M Hold
1,818,182
– – 2.09% 16
2024
Q1 		$33.2M Buy
+1,818,182
New +$28.9M 1.58% 20

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser's EWTX Position: Q4 2024 in Review

VR Adviser sold out of Edgewise Therapeutics (EWTX) in Q4 2024, closing a stake of 1,000,000 shares — an estimated $26.7M sold.

VR Adviser first reported a position in EWTX in Q1 2024 and held it in 3 quarters. The position peaked at $33.2M in Q1 2024. 200 funds tracked by Wall St. Rank hold EWTX as of Q4 2024.

  • VR Adviser reported no remaining Edgewise Therapeutics position as of Q4 2024 after selling out during the quarter.
  • VR Adviser sold 1,000,000 Edgewise Therapeutics shares in Q4 2024, an estimated $26.7M.
  • VR Adviser first reported a position in Edgewise Therapeutics in Q1 2024 and held it in 3 quarters.
  • VR Adviser's Edgewise Therapeutics position peaked at $33.2M in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2024.

Based on VR Adviser's 13F filing for Q4 2024, filed 14 Feb 2025.